First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison.

Robert MahnOscar André GlüerFarsaneh SadeghlarChristian MöhringTaotao ZhouThomas AnhaltMalte Benedikt MoninAlexander KaniaTim R GlowkaGeorg FeldmannPeter BrossartJoerg C KalffIngo G H Schmidt-WolfChristian P StrassburgMaria A Gonzalez-Carmona

Published in: Journal of hepatocellular carcinoma (2024)

Atez/Bev achieved longest median PFS and 15-mo OS independent of etiology and particularly in patients with stable liver function or prior SIRT treatment. Regarding therapy response lenvatinib was non-inferior to Atez/Bev. Finally, sorafenib seemed to perform best for patients with deteriorated liver function.

Keyphrases

oxidative stress
stem cells
replacement therapy
combination therapy
bone marrow